NasdaqCM - Nasdaq Real Time Price USD

GRI Bio, Inc. (GRI)

Compare
0.4542 -0.0099 (-2.13%)
As of 10:22 AM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Albert Agro Ph.d. Co-Founder & Chief Medical Officer 461.1k -- 1965
Ms. Leanne M. Kelly CFO & Corporate Secretary 550.93k -- 1977
Ms. Cristina Gil White Interim Chief Executive Officer -- -- --
Dr. Vipin Kumar Chaturvedi Ph.D. Co-Founder & Chief Scientific Officer -- -- 1959

GRI Bio, Inc.

2223 Avenida de la Playa
Suite 208
LA Jolla, CA 92037
United States
619 400 1170 https://www.gribio.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
4

Description

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase II clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 for the treatment of primary sclerosing cholangitis, and GRI-0729, which are in pre-clinical development. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Corporate Governance

GRI Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 12, 2024 at 9:00 PM UTC - November 18, 2024 at 9:00 PM UTC

GRI Bio, Inc. Earnings Date

Recent Events

September 6, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 23, 2024 at 12:00 AM UTC

DEFA14A: Proxy Statements

August 16, 2024 at 12:00 AM UTC

DEFA14A: Proxy Statements

August 14, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

August 2, 2024 at 12:00 AM UTC

ARS: Annual Report to Shareholders

July 26, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 23, 2024 at 12:00 AM UTC

PRE 14A: Proxy Statements

July 8, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 27, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 26, 2024 at 12:00 AM UTC

S-1/A: Offering Registrations

Related Tickers